Cardiovascular

ApoB, Lp(a) & CVD Risk: Comprehensive Guide to Lipid-Driven Cardiovascular Disease

Creator: Dr. Joshua Lindsley
Published: 2026-02-18

Dr. Joshua Lindsley, DO | Last Updated: February 2026 | 22 min read

Key Takeaways

ApoB directly counts atherogenic particles that cause heart disease—it's superior to LDL-C for risk assessment and treatment monitoring
Lp(a) is a genetic "wild card" affecting ~20% of the population that significantly increases cardiovascular risk but has limited treatment options
The "racecar analogy" helps conceptualize CVD risk: you're driving toward a cliff with foot on accelerator (risk factors) and brake (interventions)
ApoB is necessary for atherosclerosis—the more you lower it, the more you reduce risk, especially when started early
Those with elevated Lp(a) need more aggressive ApoB targets to compensate for their genetic "baseline throttle"

Summary

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death in both men and women worldwide. Understanding the lipid-driven mechanisms of atherosclerosis—particularly the roles of apolipoprotein B (apoB) and lipoprotein(a) [Lp(a)]—provides the foundation for effective prevention strategies. These biomarkers represent fundamentally different aspects of cardiovascular risk: apoB reflects the total burden of atherogenic particles and is highly modifiable, while Lp(a) is largely genetically determined and represents an independent causal risk factor that currently has limited therapeutic options.

The conceptual framework for understanding ASCVD risk can be visualized through a racecar analogy: imagine your lifespan as the distance between your current position and a cliff, with your foot on both the accelerator and brake pedals simultaneously. ApoB-containing lipoproteins, hypertension, smoking, and hyperinsulinemia press on the accelerator, speeding progress toward cardiovascular events. Lifestyle modifications and pharmacotherapy press on the brake, slowing this progression. The key insight is that you can never fully stop the car—but you can dramatically slow its forward motion by managing modifiable risk factors while understanding the baseline throttle pressure from genetic factors like Lp(a).

ApoB is a necessary, though not sufficient, factor in the development of ASCVD—meaning the more you lower it, the more you lower risk.¹ This statement reflects decades of research demonstrating that retention of apoB-containing lipoproteins within the arterial wall drives atherosclerotic plaque formation.² Unlike LDL-cholesterol (LDL-C), which measures the cholesterol content within LDL particles, apoB directly counts the number of atherogenic particles in circulation—making it a superior marker for assessing and managing cardiovascular risk.

Key Concepts at a Glance

Biomarker	What It Measures	Modifiability	Clinical Implication
ApoB	Number of atherogenic particles	Highly modifiable	Superior to LDL-C for risk assessment
Lp(a)	Genetic cardiovascular risk	Largely fixed	Affects ~20% of population
LDL-C	Cholesterol content in LDL particles	Highly modifiable	Can miss risk (discordance)
Hyperinsulinemia	Metabolic dysfunction	Modifiable	Promotes atherogenic profile

The Bottom Line

Cardiovascular disease risk is driven primarily by the cumulative exposure of apoB-containing lipoproteins to the arterial wall, modified by factors that accelerate (smoking, hypertension, hyperinsulinemia, Lp(a)) or brake (lifestyle modifications, pharmacotherapy) disease progression. ApoB is a superior marker to LDL-C for assessing risk and monitoring treatment—it directly counts the atherogenic particles that cause disease. Lp(a) represents a genetic risk factor affecting approximately 20% of the population that cannot currently be directly treated but informs how aggressively to pursue apoB lowering.

The most important clinical insight is that apoB lowering reduces cardiovascular risk in a dose-dependent manner—the lower you go, the more you reduce risk. This benefit is greatest when started early, given the cumulative nature of atherosclerotic exposure. For those with elevated Lp(a), more aggressive apoB targets are justified to compensate for the genetic "baseline throttle" that cannot be modified. Understanding these principles allows for rational, individualized cardiovascular prevention that addresses the actual drivers of disease.

Continue Reading This Evidence-Based Guide

Free access to 235+ health education guides from Highland Longevity

No spam. Unsubscribe anytime.

The Racecar Analogy: Understanding CVD Risk

The Conceptual Framework

Imagine your lifespan as driving a racecar from Point A to Point B, where Point B is driving off a cliff. You have two pedals—accelerator and brake—and your feet are always on both. The car never fully stops; it's a question of how hard you're pressing on each pedal.

Element	Cardiovascular Analogy	Modifiability
Distance to cliff	Years of remaining life	Fixed (age)
Accelerator pressure	Risk factors that promote atherosclerosis	Varies by factor
Brake pressure	Protective interventions	Highly modifiable
Baseline throttle	Genetic risk factors (e.g., Lp(a))	Largely fixed
Forward speed	Rate of atherosclerotic progression	Result of balance

Accelerators (Things That Speed You Toward the Cliff)

Risk Factor	Mechanism	Modifiability
High apoB	More atherogenic particles	Highly modifiable
Smoking	Endothelial damage, inflammation	Fully modifiable
Hypertension	Vascular injury, wall stress	Highly modifiable
Hyperinsulinemia	Upregulates APOC3, promotes atherogenic profile	Modifiable
High Lp(a)	Atherogenic particle, pro-thrombotic	Largely genetic
Diabetes	Multiple mechanisms	Partially modifiable
Inflammation	Plaque instability	Partially modifiable

Brakes (Things That Slow Your Progress)

Intervention	Mechanism	Effectiveness
ApoB-lowering drugs	Reduce atherogenic particles	Strong brake
Blood pressure control	Reduce vascular stress	Strong brake
Smoking cessation	Remove accelerator entirely	Complete brake
Dietary modification	Modest apoB reduction	Light brake
Exercise	Improves metabolic profile	Moderate brake
Weight loss	Reduces insulin resistance	Moderate brake

Key Insight: Distance Matters

Scenario	Implication	Strategy
100 feet from cliff (older, higher risk)	Need to "lock up the brakes"	Aggressive intervention
1 mile from cliff (younger, lower risk)	More judicious brake use	Prevention-focused, lifestyle emphasis
High baseline throttle (high Lp(a))	More brake pressure needed	Compensate with aggressive apoB lowering

Apolipoprotein B (ApoB) Fundamentals

What Is ApoB?

ApoB is a protein that serves as the structural scaffold for all atherogenic lipoproteins. Each atherogenic particle contains exactly one apoB molecule, making apoB a direct count of atherogenic particles.

Characteristic	Description
Definition	Primary structural protein of atherogenic lipoproteins
Measurement	Direct count of atherogenic particles
One particle = One apoB	Direct relationship, no estimation needed
Found in	LDL, VLDL, IDL, Lp(a), chylomicron remnants
Not found in	HDL

ApoB-Containing Lipoproteins

Lipoprotein	Primary Role	Atherogenic Potential
LDL	Cholesterol delivery	High (most numerous)
VLDL	Triglyceride transport	Moderate
IDL	VLDL → LDL intermediate	Moderate
Lp(a)	Unknown physiologic role	Very high (per particle)
Chylomicron remnants	Dietary fat transport	Moderate (if elevated)

Why ApoB Causes Atherosclerosis

Step	Process
1. Entry	ApoB particles enter arterial intima
2. Retention	Particles bind to proteoglycans, become trapped
3. Modification	Oxidation and other modifications occur
4. Inflammation	Macrophages engulf modified particles
5. Foam cells	Lipid-laden macrophages form foam cells
6. Plaque formation	Foam cells accumulate, plaque develops
7. Progression	Continued particle entry drives plaque growth

The Fundamental Equation

ApoB is a necessary, though not sufficient, factor in the development of ASCVD.

Necessary: Without apoB particles, atherosclerosis cannot occur
Not sufficient: Other factors influence if/when disease manifests
Implication: The more you lower apoB, the more you lower risk

ApoB vs. LDL-C: Why Particle Count Matters

Fundamental Difference

Metric	What It Measures	Limitation
LDL-C	Cholesterol mass carried in LDL particles	Doesn't count particles
ApoB	Number of atherogenic particles	Direct measurement

The Discordance Problem

LDL-C and apoB often move together but can be discordant:

Scenario	LDL-C	ApoB	Risk Assessment
Concordant high	High	High	Both predict high risk
Concordant low	Low	Low	Both predict lower risk
Discordant: Small dense LDL	Normal/low	High	Underestimated by LDL-C
Discordant: Large buoyant LDL	High	Normal	Overestimated by LDL-C

Why Particle Number Trumps Cholesterol Content

Concept	Explanation
Particles drive disease	Each particle can enter the arterial wall
Cholesterol is cargo	Amount of cholesterol per particle varies
Small dense particles	Carry less cholesterol each, but more numerous
Risk = Entry events	More particles = more chances to enter and get trapped

Evidence Favoring ApoB

Study Type	Finding
Discordance analyses	ApoB outperformed LDL-C in 9 of 9 studies
Head-to-head comparisons	ApoB significantly more accurate than non-HDL-C in 7 studies
Treatment monitoring	ApoB better reflects on-treatment risk
Mendelian randomization	Causal relationship established

When Discordance Is Most Likely

Population	Typical Pattern
Metabolic syndrome	High apoB, may have normal LDL-C
Diabetes	High apoB with small dense LDL
Familial hypercholesterolemia	Both elevated (concordant)
Very low-fat diet	May lower LDL-C more than apoB
High triglycerides	ApoB often higher than LDL-C suggests

Lipoprotein(a): The Genetic Wild Card

What Is Lp(a)?

Lp(a) is an LDL-like particle with an additional protein called apolipoprotein(a) [apo(a)] attached to the apoB molecule via a disulfide bond.

Characteristic	Description
Structure	LDL particle + apo(a) protein
Contains	One apoB molecule (contributes to total apoB)
Genetic determination	70-90% genetically determined
Physiologic function	Unknown (possibly wound healing)
Prevalence of elevated levels	~20% of population (~1.5 billion people globally)

Why Lp(a) Is Dangerous

Mechanism	Effect
Atherogenic	Carries cholesterol, enters arterial wall like LDL
Pro-thrombotic	Apo(a) resembles plasminogen, inhibits fibrinolysis
Pro-inflammatory	Carries oxidized phospholipids
Aortic valve disease	Associated with calcific aortic stenosis
Per-particle atherogenicity	~6-fold more atherogenic than LDL on per-apoB basis³

Lp(a) Risk Quantification

Lp(a) Level	Risk Category	CVD Risk Increase
<30 mg/dL (<75 nmol/L)	Optimal	Baseline
30-50 mg/dL (75-125 nmol/L)	Borderline	Modest increase
>50 mg/dL (>125 nmol/L)	Elevated	Significant increase
>100 mg/dL (>250 nmol/L)	Very high	Up to 42% greater ASCVD event risk
Highest quintile	Severely elevated	31% increased CVD risk

Lp(a) and Ethnic Differences

Population	Typical Levels	Considerations
Black/African ancestry	Higher median levels	Risk thresholds may differ
South Asian	Often elevated	Contributing factor to high CVD rates
White/European	Variable	Standard thresholds apply
East Asian	Generally lower	Lower population prevalence

Current Lp(a) Management

Approach	Status	Effect
Lifestyle	Limited impact	Generally doesn't significantly lower Lp(a)
Statins	May increase slightly	Don't target for Lp(a) lowering
Niacin	Modest reduction	Not recommended for CVD prevention
PCSK9 inhibitors	~20-30% reduction	Modest, not approved for this indication
RNA-based therapies	In clinical trials	Up to 90%+ reduction, awaiting outcomes data
Apheresis	Effective but invasive	Reserved for severe cases

Implications for Those with High Lp(a)

Strategy	Rationale
More aggressive apoB lowering	Compensate for the "baseline throttle"
Earlier intervention	Start prevention sooner
Comprehensive risk management	Address all modifiable factors
Family screening	Genetic condition, family members at risk
Monitor for aortic stenosis	Associated with calcific valve disease

Hyperinsulinemia and Metabolic Risk

How Hyperinsulinemia Promotes ASCVD

Mechanism	Effect on ASCVD Risk
APOC3 upregulation	Increases apoB, impairs clearance
LDL receptor effects	Reduces LDL clearance
Atherogenic dyslipidemia	High TG, low HDL, small dense LDL
Endothelial dysfunction	Direct vascular damage
Inflammation	Promotes vascular inflammation
Prothrombotic state	Increases clotting risk

The Metabolic Dysfunction Pathway

Step	Process	Marker
1. Insulin resistance	Tissues require more insulin	Fasting insulin, HOMA-IR
2. Compensatory hyperinsulinemia	Pancreas produces more insulin	Elevated fasting/post-meal insulin
3. Hepatic effects	Increased VLDL production	Elevated triglycerides
4. Lipoprotein changes	More small dense LDL	High apoB relative to LDL-C
5. Accelerated atherosclerosis	Multiple mechanisms converge	Increased CVD risk

The OGTT: Why It Matters

The oral glucose tolerance test (OGTT) provides more information than fasting glucose alone:

Test	What It Reveals	Limitation
Fasting glucose	Hepatic glucose production	Misses postprandial dysfunction
Fasting insulin	Baseline insulin level	Doesn't show dynamic response
OGTT (glucose)	Glucose disposal capacity	Standard diagnostic test
OGTT (insulin)	Insulin secretion pattern	Shows hyperinsulinemia early

Evidence for Hyperinsulinemia as Independent Risk Factor

Does hyperinsulinemia confer risk beyond apoB? Data suggests additional risk, but magnitude debated. The mechanism for independent risk includes endothelial dysfunction and inflammation. The clinical implication is to address insulin resistance even if apoB is controlled.

Integrating Multiple Risk Factors

Common Clinical Scenarios

Scenario	Risk Assessment	Management Approach
Low apoB, low Lp(a), good metabolic health	Lowest risk	Lifestyle maintenance
High apoB, low Lp(a)	Modifiable risk	Aggressive apoB lowering
Low apoB, high Lp(a)	Residual genetic risk	Monitor, consider more aggressive targets
High apoB, high Lp(a)	Highest risk	Maximum intervention
Good metabolic profile but elevated apoB/LDL-C	Conflicting signals	Prioritize apoB reduction
Excellent lipids but hyperinsulinemia	Hidden risk	Address metabolic dysfunction

Risk Factor Hierarchy

Priority	Risk Factor	Rationale
1	Smoking	Eliminate entirely—no safe level
2	ApoB	Necessary cause, highly modifiable
3	Blood pressure	Strong evidence, highly modifiable
4	Metabolic health	Addresses insulin resistance
5	Lp(a)	Important but limited options currently

Risk Assessment and Testing

Recommended Lipid Testing

Test	What It Measures	When to Order
Standard lipid panel	TC, LDL-C, HDL-C, TG	Baseline, routine monitoring
ApoB	Atherogenic particle count	Baseline, treatment monitoring
Lp(a)	Genetic risk factor	Once in lifetime (doesn't change)
Non-HDL-C	All apoB cholesterol	If apoB unavailable
LDL particle number	Similar to apoB	Alternative to apoB

Lp(a) Testing Considerations

Aspect	Guidance
Who to test	Everyone once; universal screening recommended
When to test	Any time—levels are stable
Repeat testing	Generally unnecessary (genetically determined)
Units	mg/dL or nmol/L (not directly convertible)
Family implications	Test first-degree relatives if elevated

Metabolic Assessment

Test	Purpose	Frequency
Fasting glucose	Screen for diabetes	Annually
HbA1c	Glycemic control	Annually
Fasting insulin	Assess insulin resistance	Baseline, as indicated
OGTT with insulin	Early detection of dysfunction	As clinically indicated
HOMA-IR	Calculated insulin resistance	Research, clinical interest

Interpreting Results in Context

Finding	Interpretation	Action
High apoB, normal LDL-C	More particles, each carrying less cholesterol	Treat based on apoB
Elevated Lp(a)	Genetic risk present	More aggressive apoB targets
High TG, low HDL-C	Metabolic dysfunction likely	Assess insulin resistance
Discordant apoB/LDL-C	apoB is more accurate	Use apoB for decisions

Therapeutic Targets and Strategies

ApoB Targets (2024 Consensus)¹

Risk Category	ApoB Target	LDL-C Approximate Equivalent
Low risk	<100 mg/dL	<130 mg/dL
Intermediate risk	<90 mg/dL	<115 mg/dL
High risk	<70 mg/dL	<70 mg/dL
Very high risk	<60 mg/dL	<55 mg/dL
With elevated Lp(a)	Consider more aggressive	Lower targets justified

ApoB-Lowering Therapies

Therapy	ApoB Reduction	Notes
High-intensity statin	40-50%	First-line therapy
Ezetimibe	Additional 15-20%	Add to statin
PCSK9 inhibitors	Additional 50-60%	For high-risk, inadequate response
Bempedoic acid	15-25%	Statin-intolerant option
Inclisiran	50%+	Twice-yearly injection
Diet (modest)	5-15%	Portfolio diet, plant sterols

Blood Pressure Targets

Population	Target	Evidence Level
General	<130/80 mmHg	Strong (SPRINT)
High CVD risk	<120/80 mmHg	Strong
Elderly (fit)	<130/80 mmHg	Moderate
Elderly (frail)	Individualized	Limited

Metabolic Health Interventions

Intervention	Impact	Priority
Weight loss	Improves insulin sensitivity	High for overweight/obese
Exercise	Independent metabolic benefits	High for all
Carbohydrate modification	Reduces insulin demand	High for insulin resistant
Medications (metformin, GLP-1, etc.)	Various mechanisms	As indicated

Starting Early: The Case for Prevention

Why Timing Matters

Concept	Explanation
Cumulative exposure	Total apoB exposure over lifetime drives disease
Area under curve	Lower apoB × more years = less total exposure
Early calcification	Even young adults have evidence of plaque
Reversibility	Early disease more modifiable than advanced
"Lock up brakes" scenario	Starting late requires much more aggressive intervention

Familial Hypercholesterolemia Data

Studies of individuals with genetically high LDL-C/apoB demonstrate:

Finding	Implication
Earlier CVD onset	Lifetime exposure drives disease
Dose-response relationship	Higher levels = earlier events
Treatment benefit	Even partial correction helps
Natural experiment	Proves causality of apoB

Age-Based Strategy

Age	Risk Level	Approach
20s-30s	Building foundation	Know your numbers, lifestyle optimization
30s-40s	Early prevention	Address elevated apoB, Lp(a) testing
40s-50s	Active prevention	Consider pharmacotherapy if indicated
50s-60s	Aggressive prevention	Most patients benefit from treatment
60s+	Late but valuable	Still meaningful risk reduction

Calcium Score Context

CAC Score	Interpretation	Treatment Implications
0	No detected calcified plaque	Lower near-term risk, but not zero
1-100	Mild calcification	Confirms plaque presence, treat risk factors
101-400	Moderate calcification	Increased risk, aggressive management
>400	Severe calcification	High risk, intensive therapy

Clinical Decision-Making Scenarios

Scenario 1: Young Person with Elevated LDL-C

Factor	Finding	Decision
Age	35 years	Far from "cliff"
LDL-C	180 mg/dL	Elevated
ApoB	150 mg/dL	Confirmed elevated
Lp(a)	Normal	No genetic amplifier
Other risk factors	None	Low short-term risk
Approach	Lifestyle first, consider statin if persistent	Balance long-term benefit vs. decades of treatment

Scenario 2: Middle-Aged with Metabolic Syndrome

Factor	Finding	Decision
Age	50 years	Moderate distance to "cliff"
LDL-C	110 mg/dL	"Normal"
ApoB	105 mg/dL	Elevated (discordant)
Lp(a)	Normal	No genetic amplifier
Metabolic markers	High TG, low HDL, elevated insulin	Significant accelerator
Approach	Address metabolic health AND lower apoB	Both accelerators need attention

Scenario 3: Elevated Lp(a)

Factor	Finding	Decision
Lp(a)	180 nmol/L	Very elevated
ApoB	85 mg/dL	Borderline
Other factors	Well-controlled	Genetic throttle is main issue
Approach	More aggressive apoB target (<60 mg/dL)	Compensate for non-modifiable risk
Family	Screen first-degree relatives	Genetic condition

Scenario 4: Hesitancy About Medications

Concern	Response
"I want to do it naturally"	Lifestyle is important but may be insufficient
"Statins have side effects"	True myopathy rare; benefits outweigh risks for most
"I'm young, I don't need drugs"	Cumulative exposure argument; earlier is better
"My cholesterol isn't that high"	apoB is what matters; relative to optimal, not average
Practical framing	Small daily action (pill) for large lifetime benefit

Summary Tables

The Big Three ASCVD Drivers

Factor	Mechanism	Intervention
Smoking	Endothelial damage, inflammation, thrombosis	Complete cessation
Hypertension	Vascular injury, wall stress	<130/80 mmHg
ApoB	Particle entry and retention in artery	Lower with lifestyle + meds

Additional Important Factors

Factor	Role	Management
Lp(a)	Genetic accelerator	Know your level, compensate with apoB lowering
Hyperinsulinemia	Promotes atherogenic profile	Address metabolic dysfunction
Inflammation	Plaque instability	Address underlying causes
Diabetes	Multiple mechanisms	Comprehensive management

Testing Summary

Test	Timing	Frequency
Standard lipids	Baseline	Every 4-6 years (more if treating)
ApoB	Baseline	Treatment monitoring
Lp(a)	Once	No need to repeat
Metabolic panel	Baseline	Annual
OGTT	As indicated	When insulin resistance suspected

Additional Considerations

Study Limitations

Discordance analyses¹: Observational data comparing apoB vs LDL-C; limited randomized trials directly testing apoB-guided therapy.
Lp(a) atherogenicity estimates³: Based on Mendelian randomization; actual clinical impact varies with absolute levels and other risk factors.
Ethnic-specific thresholds: Most guidelines based on European/White populations; optimal thresholds for other populations less established.

Conflicting Evidence

apoB vs non-HDL-C: Some analyses show non-HDL-C performs similarly to apoB; NLA consensus favors apoB for direct particle measurement.
Niacin for Lp(a): While niacin lowers Lp(a) by ~20-30%, the AIM-HIGH and HPS2-THRIVE trials showed no cardiovascular benefit when added to statins.
Very low LDL/apoB targets: Some controversy exists regarding optimal lower limits; extremely low levels appear safe in long-term genetic studies.

Individual Variation

apoB-LDL-C discordance: Most pronounced in metabolic syndrome, diabetes, and high triglyceride states; less relevant when lipid profile is concordant.
Statin response variability: LDL-C/apoB reduction ranges from 20-60% depending on genetic factors (SLCO1B1 variants).
Lp(a) levels: Vary substantially by ethnicity; Black/African ancestry populations have higher median levels.

Safety Notes

Statin myopathy: True myopathy rare (<0.1%); muscle symptoms often related to nocebo effect.
Very low apoB levels: Genetic evidence from familial hypobetalipoproteinemia suggests very low levels are safe.
Drug interactions: PCSK9 inhibitors well-tolerated; bempedoic acid may increase tendon rupture risk.

Evidence Gaps

apoB-guided RCTs: No large randomized trials directly compare apoB-targeted vs LDL-C-targeted therapy for outcomes.
Lp(a)-lowering outcomes: Awaiting Phase 3 trial results (Lp(a)HORIZON for pelacarsen) to confirm cardiovascular benefit.⁴
Optimal targets by age: Whether younger patients benefit from more aggressive targets remains under investigation.

Recent Developments

2024 NLA apoB Consensus¹: First comprehensive expert consensus specifically addressing apoB measurement and clinical use.
Lp(a) therapeutics⁴: Pelacarsen Phase 3 outcomes expected H1 2026; olpasiran in Phase 3.
JACC Lp(a) atherogenicity³: 2024 study quantified ~6-fold greater per-particle atherogenicity of Lp(a) versus LDL.

References

Ballantyne, C. M., Bays, H. E., Braun, L. T., et al. (2024). Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. Journal of Clinical Lipidology, 18(5), e647-e663. doi:10.1016/j.jacl.2024.08.007
Ference, B. A., Ginsberg, H. N., Graham, I., et al. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38(32), 2459-2472. doi:10.1093/eurheartj/ehx144
Björnson, E., Adiels, M., Taskinen, M. R., et al. (2024). Lipoprotein(a) is markedly more atherogenic than LDL: An apolipoprotein B-based genetic analysis. Journal of the American College of Cardiology, 83(3), 385-395. doi:10.1016/j.jacc.2023.10.039
Rider, D. A., Eisermann, M., Germann, K., et al. (2022). Lp(a)HORIZON: Design and rationale of a Phase 3 cardiovascular outcomes study evaluating pelacarsen in patients with established CVD and elevated Lp(a). American Heart Journal, 246, 1-11. doi:10.1016/j.ahj.2021.12.008

Medical Disclaimer: This educational brief is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting any new health regimen. Individual results may vary. The information presented reflects current research as of February 2026 and may be updated as new evidence becomes available.